136 related articles for article (PubMed ID: 12200671)
1. Clinical efficacy and antiangiogenic activity of thalidomide in myelofibrosis with myeloid metaplasia. A pilot study.
Piccaluga PP; Visani G; Pileri SA; Ascani S; Grafone T; Isidori A; Malagola M; Finelli C; Martinelli G; Ricci P; Baccarani M; Tura S
Leukemia; 2002 Sep; 16(9):1609-14. PubMed ID: 12200671
[TBL] [Abstract][Full Text] [Related]
2. Thalidomide therapy for myelofibrosis with myeloid metaplasia.
Thomas DA; Giles FJ; Albitar M; Cortes JE; Verstovsek S; Faderl S; O'Brien SM; Garcia-Manero G; Keating MJ; Pierce S; Zeldis J; Kantarjian HM
Cancer; 2006 May; 106(9):1974-84. PubMed ID: 16583431
[TBL] [Abstract][Full Text] [Related]
3. Tumor angiogenesis in the bone marrow of multiple myeloma patients and its alteration by thalidomide treatment.
Du W; Hattori Y; Hashiguchi A; Kondoh K; Hozumi N; Ikeda Y; Sakamoto M; Hata J; Yamada T
Pathol Int; 2004 May; 54(5):285-94. PubMed ID: 15086832
[TBL] [Abstract][Full Text] [Related]
4. High plasma basic fibroblast growth factor concentration is associated with response to thalidomide in progressive multiple myeloma.
Neben K; Moehler T; Egerer G; Kraemer A; Hillengass J; Benner A; Ho AD; Goldschmidt H
Clin Cancer Res; 2001 Sep; 7(9):2675-81. PubMed ID: 11555579
[TBL] [Abstract][Full Text] [Related]
5. A phase II trial of thalidomide in patients with refractory leiomyosarcoma of the uterus and correlation with biomarkers of angiogenesis: a gynecologic oncology group study.
McMeekin DS; Sill MW; Darcy KM; Stearns-Kurosawa DJ; Webster K; Waggoner S; Benbrook D
Gynecol Oncol; 2007 Sep; 106(3):596-603. PubMed ID: 17597196
[TBL] [Abstract][Full Text] [Related]
6. [Therapeutic effectiveness of thalidomide to multiple myeloma and its mechanism].
Wang M; Liu Y; Li Y; Wu H
Zhonghua Xue Ye Xue Za Zhi; 2002 Oct; 23(10):514-6. PubMed ID: 12482346
[TBL] [Abstract][Full Text] [Related]
7. Angiogenic factors in multiple myeloma: higher levels in bone marrow than in peripheral blood.
Di Raimondo F; Azzaro MP; Palumbo G; Bagnato S; Giustolisi G; Floridia P; Sortino G; Giustolisi R
Haematologica; 2000 Aug; 85(8):800-5. PubMed ID: 10942925
[TBL] [Abstract][Full Text] [Related]
8. Low-dose thalidomide ameliorates cytopenias and splenomegaly in myelofibrosis with myeloid metaplasia: a phase II trial.
Marchetti M; Barosi G; Balestri F; Viarengo G; Gentili S; Barulli S; Demory JL; Ilariucci F; Volpe A; Bordessoule D; Grossi A; Le Bousse-Kerdiles MC; Caenazzo A; Pecci A; Falcone A; Broccia G; Bendotti C; Bauduer F; Buccisano F; Dupriez B
J Clin Oncol; 2004 Feb; 22(3):424-31. PubMed ID: 14752066
[TBL] [Abstract][Full Text] [Related]
9. Angiogenesis and anti-angiogenic therapy in myelofibrosis with myeloid metaplasia.
Arora B; Mesa R; Tefferi A
Leuk Lymphoma; 2004 Dec; 45(12):2373-86. PubMed ID: 15621750
[TBL] [Abstract][Full Text] [Related]
10. Production of proangiogenic cytokines during thalidomide treatment of multiple myeloma.
Dmoszyńska A; Bojarska-Junak A; Domański D; Roliński J; Hus M; Soroka-Wojtaszko M
Leuk Lymphoma; 2002 Feb; 43(2):401-6. PubMed ID: 11999576
[TBL] [Abstract][Full Text] [Related]
11. Thalidomide for the treatment of idiopathic myelofibrosis.
Strupp C; Germing U; Scherer A; Kündgen A; Mödder U; Gattermann N; Haas R
Eur J Haematol; 2004 Jan; 72(1):52-7. PubMed ID: 14962263
[TBL] [Abstract][Full Text] [Related]
12. Elevated vascular endothelial growth factor (VEGF) serum levels in idiopathic myelofibrosis.
Di Raimondo F; Azzaro MP; Palumbo GA; Bagnato S; Stagno F; Giustolisi GM; Cacciola E; Sortino G; Guglielmo P; Giustolisi R
Leukemia; 2001 Jun; 15(6):976-80. PubMed ID: 11417486
[TBL] [Abstract][Full Text] [Related]
13. The combination of intermediate doses of thalidomide and dexamethasone reduces bone marrow micro-vessel density but not serum levels of angiogenic cytokines in patients with refractory/relapsed multiple myeloma.
Hatjiharissi E; Terpos E; Papaioannou M; Hatjileontis C; Kaloutsi V; Galaktidou G; Gerotziafas G; Christakis J; Zervas K
Hematol Oncol; 2004 Dec; 22(4):159-68. PubMed ID: 15991268
[TBL] [Abstract][Full Text] [Related]
14. Thalidomide in advanced hepatocellular carcinoma as antiangiogenic treatment approach: a phase I/II trial.
Pinter M; Wichlas M; Schmid K; Plank C; Müller C; Wrba F; Peck-Radosavljevic M
Eur J Gastroenterol Hepatol; 2008 Oct; 20(10):1012-9. PubMed ID: 18787470
[TBL] [Abstract][Full Text] [Related]
15. A phase II study of razoxane, an antiangiogenic topoisomerase II inhibitor, in renal cell cancer with assessment of potential surrogate markers of angiogenesis.
Braybrooke JP; O'Byrne KJ; Propper DJ; Blann A; Saunders M; Dobbs N; Han C; Woodhull J; Mitchell K; Crew J; Smith K; Stephens R; Ganesan TS; Talbot DC; Harris AL
Clin Cancer Res; 2000 Dec; 6(12):4697-704. PubMed ID: 11156222
[TBL] [Abstract][Full Text] [Related]
16. A randomized phase II trial of thalidomide, an angiogenesis inhibitor, in patients with androgen-independent prostate cancer.
Figg WD; Dahut W; Duray P; Hamilton M; Tompkins A; Steinberg SM; Jones E; Premkumar A; Linehan WM; Floeter MK; Chen CC; Dixon S; Kohler DR; Krüger EA; Gubish E; Pluda JM; Reed E
Clin Cancer Res; 2001 Jul; 7(7):1888-93. PubMed ID: 11448901
[TBL] [Abstract][Full Text] [Related]
17. Bone marrow immunohistochemical studies of angiogenic cytokines and their receptors in myelofibrosis with myeloid metaplasia.
Chou JM; Li CY; Tefferi A
Leuk Res; 2003 Jun; 27(6):499-504. PubMed ID: 12648509
[TBL] [Abstract][Full Text] [Related]
18. A non-randomised dose-escalating phase II study of thalidomide for the treatment of patients with low-risk myelodysplastic syndromes: the Thal-SMD-2000 trial of the Groupe Français des Myélodysplasies.
Bouscary D; Legros L; Tulliez M; Dubois S; Mahe B; Beyne-Rauzy O; Quarre MC; Vassilief D; Varet B; Aouba A; Gardembas M; Giraudier S; Guerci A; Rousselot P; Gaillard F; Moreau A; Rousselet MC; Ifrah N; Fenaux P; Dreyfus F;
Br J Haematol; 2005 Dec; 131(5):609-18. PubMed ID: 16351636
[TBL] [Abstract][Full Text] [Related]
19. Bone marrow expression of vascular endothelial growth factor in myelofibrosis with myeloid metaplasia.
Ho CL; Arora B; Hoyer JD; Wellik LE; Mesa RA; Tefferi A
Eur J Haematol; 2005 Jan; 74(1):35-9. PubMed ID: 15613104
[TBL] [Abstract][Full Text] [Related]
20. Are basic fibroblast growth factor and vascular endothelial growth factor prognostic indicators in pediatric patients with malignant solid tumors?
Tabone MD; Landman-Parker J; Arcil B; Coudert MC; Gerota I; Benbunan M; Leverger G; Dosquet C
Clin Cancer Res; 2001 Mar; 7(3):538-43. PubMed ID: 11297245
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]